Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 1/20 | 0.76 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.71 |
| ▸ | MEN1 | O00255 | 5/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | MAPT | P10636 | 4/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | HTT | P42858 | 2/20 | 0.68 |
| ▸ | USP2 | O75604 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | GFER | P55789 | 1/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL14053708 | 0.99 | MMP9 (0.74) | MMP9PIK3CGMEN1KMT2APOLB | |
| SCHEMBL4524394 | 0.90 | ALDH1A1 (0.78) | MMP9PIK3CGMEN1KMT2APOLB | |
| SCHEMBL14146803 | 0.88 | PIK3CG (0.76) | MMP9PIK3CGMEN1KMT2APOLB | |
| SCHEMBL4511244 | 0.88 | MMP9 (0.74) | MMP9PIK3CGMEN1KMT2APOLB | |
| Hydrochloric Acid SCHEMBL14053781 | 0.87 | MMP9 (0.73) | MMP9PIK3CGMEN1KMT2APOLB | |
| SCHEMBL8738344 | 0.87 | MMP9 (0.73) | MMP9PIK3CGMEN1KMT2APOLB | |
| SCHEMBL14146824 | 0.87 | MMP9 (0.73) | MMP9PIK3CGMEN1KMT2APOLB | |
| SCHEMBL4522975 | 0.87 | MMP9 (0.73) | MMP9PIK3CGMEN1KMT2APOLB | |
| SCHEMBL29394354 | 0.86 | MMP9 (1.00) | MMP9MEN1KMT2AALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL14053885 | 0.86 | MMP9 (0.71) | MMP9PIK3CGMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802861-B2 | Thiazole derivatives and use thereof | MERCK SERONO SA (CH) | 2014-08-12 | — | — | US | claimed |
| US-20090029998-A1 | Thiazole Derivatives and Use Thereof | APPLIED RESEARCH SYSTEM ARS HOLDING N.V. (NL) | 2009-01-29 | — | — | US | claimed |
| EP-1709019-B1 | THIAZOLE DERIVATIVES AND USE THEREOF | APPLIED RESEARCH SYSTEMS (AN) | 2007-08-08 | — | — | EP | claimed |
| US-9150561-B2 | Thiazole derivatives and use thereof | MERCK SERONO S.A. (CH) | 2015-10-06 | — | — | US | disclosed |
| US-9150561-B2 | Thiazole derivatives and use thereof | MERCK SERONO S.A. (CH) | 2015-10-06 | — | — | US | disclosed |
| US-9150561-B2 | Thiazole derivatives and use thereof | MERCK SERONO S.A. (CH) | 2015-10-06 | — | — | US | disclosed |
| US-20140228365-A1 | THIAZOLE DERIVATIVES AND USE THEREOF | MERCK SERONO S.A. (CH) | 2014-08-14 | — | — | US | disclosed |
| US-20140228365-A1 | THIAZOLE DERIVATIVES AND USE THEREOF | MERCK SERONO S.A. (CH) | 2014-08-14 | — | — | US | disclosed |
| US-20140228365-A1 | THIAZOLE DERIVATIVES AND USE THEREOF | MERCK SERONO S.A. (CH) | 2014-08-14 | — | — | US | disclosed |
| US-8802861-B2 | Thiazole derivatives and use thereof | MERCK SERONO SA (CH) | 2014-08-12 | — | — | US | disclosed |
| US-8802861-B2 | Thiazole derivatives and use thereof | MERCK SERONO SA (CH) | 2014-08-12 | — | — | US | disclosed |
| US-8802861-B2 | Thiazole derivatives and use thereof | MERCK SERONO SA (CH) | 2014-08-12 | — | — | US | disclosed |
| US-20120302573-A1 | METHODS OF INHIBITING PRO MATRIX METALLOPROTEINASE ACTIVATION | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-29 | — | — | US | disclosed |
| WO-2012162468-A1 | THIAZOL DERIVATIVES AS PRO -MATRIX METALLOPROTEINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-29 | — | — | WO | disclosed |
| WO-2012162468-A1 | THIAZOL DERIVATIVES AS PRO -MATRIX METALLOPROTEINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-29 | — | — | WO | disclosed |
| US-20120302573-A1 | METHODS OF INHIBITING PRO MATRIX METALLOPROTEINASE ACTIVATION | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-29 | — | — | US | disclosed |
| US-20120302573-A1 | METHODS OF INHIBITING PRO MATRIX METALLOPROTEINASE ACTIVATION | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-29 | — | — | US | disclosed |
| US-20090029998-A1 | Thiazole Derivatives and Use Thereof | APPLIED RESEARCH SYSTEM ARS HOLDING N.V. (NL) | 2009-01-29 | — | — | US | disclosed |
| US-20090029998-A1 | Thiazole Derivatives and Use Thereof | APPLIED RESEARCH SYSTEM ARS HOLDING N.V. (NL) | 2009-01-29 | — | — | US | disclosed |
| US-20090029998-A1 | Thiazole Derivatives and Use Thereof | APPLIED RESEARCH SYSTEM ARS HOLDING N.V. (NL) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228365-A1 | THIAZOLE DERIVATIVES AND USE THEREOF | PF4, TEC, PDGFRB | MMP9 2730/4885PIK3CG 2806/4885MEN1 1164/4885 |
| US-20120302573-A1 | METHODS OF INHIBITING PRO MATRIX METALLOPROTEINASE ACTIVATION | MMP13, MMP8, MMP11 | MMP9 8/4885PIK3CG 4407/4885MEN1 2970/4885 |
| US-20090029998-A1 | Thiazole Derivatives and Use Thereof | PDGFRB, PDGFRA, TEC | MMP9 3787/4885PIK3CG 2526/4885MEN1 1761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.